[ECG Score to Predict ICD Therapies in Patients with Nonischemic Cardiomyopathy and Primary Prophylactic CRT-D]

Overview

Journal Herzschrittmacherther Elektrophysiol

Date 2017 Feb 17

PMID 28204917

Citations 1

Authors

Martin Grett

Martin Christ

Jan-Peter Roing Gen Nolke

Hans-Joachim Trappe

Affiliations

Soon will be listed here.

Abstract

Background And Problem: Recently published results of the DANISH study raise concerns, if primary prophylactic ICD implantations in patients with nonischemic cardiomyopathy (NICM) and severe reduced left ventricular ejection fraction (LVEF) should be performed without further risk stratification. There was no significant difference in the overall mortality of patients with or without ICD and CRT defibrillator (CRT-D) or CRT pacemaker (CRT-P), respectively. Clinical risk scores to identify patients with ischemic cardiomyopathy (ICM) who benefit most from an ICD have been recommended. The need for risk stratification systems concerning patients with NICM has been emphasized.

Study Design And Methods: A retrospective study of 434 consecutive patients with CRT-D implantation was performed. Patients with no regular follow-up at our institution (n = 132), secondary prophylactic ICD indication (n = 61), and upgrade to CRT (n = 95) were excluded. The occurrence of an adequate ICD therapy was defined as the endpoint. Left ventricular ejection fraction (LVEF), genesis of the cardiomyopathy as well as the modified Selvester ECG score (MSES) for evaluation of the left ventricular scar burden were documented among other characteristics.

Results: Within a median follow-up of 605 days, 24% of the patients experienced an adequate ICD therapy. These patients had significantly lower LVEF (20% vs. 23%), and the MSES was higher (7 vs. 3 points). There was no significant difference in patients suffering from ICM vs NICM. A receiver-operating-characteristic (ROC) analysis revealed a sensitivity of 0.914 and a specifity of 0.586 for MSES ≥4 to predict the occurrence of an ICD therapy. None of 35 patients suffering from NICM with MSES <4 experienced an ICD therapy.

Interpretation: The evaluation of the left ventricular scar burden using MSES can be useful for the decision between CRT-D and CRT-P in patients suffering from NICM.

Citing Articles

Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.

Jilek C, Lewalter T, Pauschinger M, von Scheidt W, Frankenstein L, Pfister O Clin Res Cardiol. 2019; 109(1):115-123.

PMID: 31236690 DOI: 10.1007/s00392-019-01503-0.

References

Iles L, Pfluger H, Lefkovits L, Butler M, Kistler P, Kaye D . Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011; 57(7):821-8. DOI: 10.1016/j.jacc.2010.06.062. View

Kober L, Thune J, Nielsen J, Haarbo J, Videbaek L, Korup E . Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016; 375(13):1221-30. DOI: 10.1056/NEJMoa1608029. View

Loring Z, Chelliah S, Selvester R, Wagner G, Strauss D . A detailed guide for quantification of myocardial scar with the Selvester QRS score in the presence of electrocardiogram confounders. J Electrocardiol. 2011; 44(5):544-54. PMC: 3164517. DOI: 10.1016/j.jelectrocard.2011.06.008. View

Kadish A, Dyer A, Daubert J, Quigg R, Mark Estes N, Anderson K . Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004; 350(21):2151-8. DOI: 10.1056/NEJMoa033088. View

Disertori M, Quintarelli S, Mazzola S, Favalli V, Narula N, Arbustini E . The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. Europace. 2013; 15(12):1693-701. DOI: 10.1093/europace/eut228. View

Kirkfeldt R, Johansen J, Nohr E, Jorgensen O, Nielsen J . Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2013; 35(18):1186-94. PMC: 4012708. DOI: 10.1093/eurheartj/eht511. View

Scott P, Morgan J, Carroll N, Murday D, Roberts P, Peebles C . The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 2011; 4(3):324-30. DOI: 10.1161/CIRCEP.110.959544. View

Felker G, Shaw L, OConnor C . A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002; 39(2):210-8. DOI: 10.1016/s0735-1097(01)01738-7. View

Bardy G, Lee K, Mark D, Poole J, Packer D, Boineau R . Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352(3):225-37. DOI: 10.1056/NEJMoa043399. View

10.

Barsheshet A, Wang P, Moss A, Solomon S, Al-Ahmad A, McNitt S . Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011; 57(24):2416-23. DOI: 10.1016/j.jacc.2010.12.041. View

11.

Barsheshet A, Moss A, Huang D, McNitt S, Zareba W, Goldenberg I . Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 2012; 59(23):2075-9. DOI: 10.1016/j.jacc.2012.02.036. View

12.

Strauss D, Selvester R . The QRS complex--a biomarker that "images" the heart: QRS scores to quantify myocardial scar in the presence of normal and abnormal ventricular conduction. J Electrocardiol. 2008; 42(1):85-96. DOI: 10.1016/j.jelectrocard.2008.07.011. View

13.

Sweeney M, van Bommel R, Schalij M, Borleffs C, Hellkamp A, Bax J . Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. Circulation. 2010; 121(5):626-34. DOI: 10.1161/CIRCULATIONAHA.109.894774. View

14.

Fernandez-Armenta J, Berruezo A, Mont L, Sitges M, Andreu D, Silva E . Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace. 2012; 14(11):1578-86. DOI: 10.1093/europace/eus104. View

15.

Strauss D, Poole J, Wagner G, Selvester R, Miller J, Anderson J . An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. Heart Rhythm. 2010; 8(1):38-45. PMC: 3010478. DOI: 10.1016/j.hrthm.2010.09.071. View